Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years

Last Updated: Wednesday, December 15, 2021

An age-based analysis of the FDA Adverse Events Reporting System (FAERS) database revealed differences in patterns of adverse events experienced by patients aged < 65 and ≥ 65 treated with axicabtagene ciloleucel and tisagenlecleucel.

Journal of Geriatric Oncology

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

Journal of Blood Medicine

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Biology of Blood and Marrow Transplantation

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Expert Review of Anti-Infective Therapy

CAR-T Cell Therapy and Infection: A Review

Blood Advances

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

The ASCO Post

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Nature Reviews Clinical Oncology

Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Journal of Clinical Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Journal of the Advanced Practitioner in Oncology

CAR T-Cell Therapy: Adverse Events and Management

CAR T-Cell Therapy Resource Center

Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

Journal of Blood Medicine

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Biology of Blood and Marrow Transplantation

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Expert Review of Anti-Infective Therapy

CAR-T Cell Therapy and Infection: A Review

Blood Advances

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

The ASCO Post

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Nature Reviews Clinical Oncology

Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Journal of Clinical Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Journal of the Advanced Practitioner in Oncology

CAR T-Cell Therapy: Adverse Events and Management

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Neurologic Toxicity Post-CAR T-Cell Therapy and CRS: Differentiating Symptoms and Individual Management

Fast Facts #12: BCMA Targets

Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years

Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years